Day One Biopharmaceuticals (DAWN) Competitors $12.43 +0.20 (+1.64%) Closing price 04:00 PM EasternExtended Trading$12.46 +0.04 (+0.28%) As of 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DAWN vs. TGTX, KRYS, SWTX, BHVN, RXRX, PTCT, OGN, RARE, ALVO, and RNAShould you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include TG Therapeutics (TGTX), Krystal Biotech (KRYS), SpringWorks Therapeutics (SWTX), Biohaven (BHVN), Recursion Pharmaceuticals (RXRX), PTC Therapeutics (PTCT), Organon & Co. (OGN), Ultragenyx Pharmaceutical (RARE), Alvotech (ALVO), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry. Day One Biopharmaceuticals vs. TG Therapeutics Krystal Biotech SpringWorks Therapeutics Biohaven Recursion Pharmaceuticals PTC Therapeutics Organon & Co. Ultragenyx Pharmaceutical Alvotech Avidity Biosciences Day One Biopharmaceuticals (NASDAQ:DAWN) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment. Do insiders and institutionals believe in DAWN or TGTX? 88.0% of Day One Biopharmaceuticals shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 8.4% of Day One Biopharmaceuticals shares are owned by insiders. Comparatively, 10.5% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community prefer DAWN or TGTX? TG Therapeutics received 610 more outperform votes than Day One Biopharmaceuticals when rated by MarketBeat users. Likewise, 76.33% of users gave TG Therapeutics an outperform vote while only 67.61% of users gave Day One Biopharmaceuticals an outperform vote. CompanyUnderperformOutperformDay One BiopharmaceuticalsOutperform Votes4867.61% Underperform Votes2332.39% TG TherapeuticsOutperform Votes65876.33% Underperform Votes20423.67% Which has preferable earnings and valuation, DAWN or TGTX? TG Therapeutics has higher revenue and earnings than Day One Biopharmaceuticals. TG Therapeutics is trading at a lower price-to-earnings ratio than Day One Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDay One BiopharmaceuticalsN/AN/A-$188.92M-$1.03-12.08TG Therapeutics$233.66M20.36$12.67M-$0.10-305.61 Does the media favor DAWN or TGTX? In the previous week, TG Therapeutics had 5 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 7 mentions for TG Therapeutics and 2 mentions for Day One Biopharmaceuticals. TG Therapeutics' average media sentiment score of 1.31 beat Day One Biopharmaceuticals' score of 0.92 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Day One Biopharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, DAWN or TGTX? Day One Biopharmaceuticals has a beta of -1.46, indicating that its share price is 246% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500. Is DAWN or TGTX more profitable? Day One Biopharmaceuticals has a net margin of 0.00% compared to TG Therapeutics' net margin of -5.42%. TG Therapeutics' return on equity of -8.32% beat Day One Biopharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Day One BiopharmaceuticalsN/A -22.40% -19.79% TG Therapeutics -5.42%-8.32%-3.40% Do analysts rate DAWN or TGTX? Day One Biopharmaceuticals currently has a consensus price target of $35.71, suggesting a potential upside of 187.07%. TG Therapeutics has a consensus price target of $40.67, suggesting a potential upside of 33.05%. Given Day One Biopharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Day One Biopharmaceuticals is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Day One Biopharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 SummaryTG Therapeutics beats Day One Biopharmaceuticals on 11 of the 18 factors compared between the two stocks. Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DAWN vs. The Competition Export to ExcelMetricDay One BiopharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.25B$7.04B$5.78B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-12.076.1326.4618.82Price / SalesN/A312.32457.0180.82Price / CashN/A67.8344.0437.47Price / Book3.126.747.634.64Net Income-$188.92M$138.11M$3.18B$245.69M7 Day Performance1.39%-2.02%-1.82%-2.63%1 Month Performance1.55%-1.54%0.22%-2.37%1 Year Performance-15.73%-3.14%17.49%13.65% Day One Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAWNDay One Biopharmaceuticals2.1092 of 5 stars$12.43+1.6%$35.71+187.3%-17.9%$1.25BN/A-12.0760Upcoming EarningsInsider TradeNews CoverageTGTXTG Therapeutics4.4797 of 5 stars$30.71-0.1%$40.67+32.4%+133.9%$4.78B$233.66M-307.07290Positive NewsKRYSKrystal Biotech4.4767 of 5 stars$153.24-1.6%$206.67+34.9%+63.6%$4.41B$50.70M86.58210Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageSWTXSpringWorks Therapeutics1.2527 of 5 stars$57.43-2.0%$70.83+23.3%+22.8%$4.27B$5.45M-14.80230Earnings ReportAnalyst ForecastInsider TradeNews CoverageBHVNBiohaven3.3776 of 5 stars$41.45-0.8%$63.15+52.4%-15.8%$4.19BN/A-4.43239Short Interest ↓RXRXRecursion Pharmaceuticals1.5231 of 5 stars$10.53+23.9%$8.75-16.9%-17.8%$4.11B$64.60M-6.88400High Trading VolumePTCTPTC Therapeutics3.6197 of 5 stars$51.82+4.3%$58.85+13.6%+93.9%$4.00B$937.82M-8.721,410Analyst ForecastNews CoverageOGNOrganon & Co.4.8637 of 5 stars$15.30-6.3%$20.80+36.0%-15.2%$3.94B$6.26B3.0310,000RAREUltragenyx Pharmaceutical4.6097 of 5 stars$42.49-2.4%$92.43+117.5%-7.1%$3.92B$434.25M-6.571,276Analyst ForecastALVOAlvotech2.6284 of 5 stars$12.99+1.6%$18.00+38.6%-26.7%$3.92B$391.87M-7.021,026News CoverageRNAAvidity Biosciences1.613 of 5 stars$32.31-2.2%$65.80+103.7%+132.7%$3.85B$9.56M-11.22190 Related Companies and Tools Related Companies TG Therapeutics Competitors Krystal Biotech Competitors SpringWorks Therapeutics Competitors Biohaven Competitors Recursion Pharmaceuticals Competitors PTC Therapeutics Competitors Organon & Co. Competitors Ultragenyx Pharmaceutical Competitors Alvotech Competitors Avidity Biosciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DAWN) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DAWN Stock Alerts